ScripWho: Grünenthal/Valinor Pharma What: Grünenthal is buying privately held US biotech Valinor on the strength of its lone commercial product, Movantik. Why: Grünenthal is acquiring Valinor to gain
ScripPrivately held Soterios Pharma unveiled positive top-line Phase II data for its alopecia areata candidate STS-01 on 30 May, saying the drug could be positioned to compete with established JAK inhibi
ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Bristol Looks Into Tolerizing Vaccines,
ScripOnce seen as the next big thing in cancer, cytokine-based therapies lost their shine after numerous trial flops, but Synthekine is among a number of companies that believe they can succeed with a ne